naa a22 4500 51077962X CHVBK 20180411083242.0 cr unu---uuuuu 180411e20130601xx s 000 0 eng 10.1007/s11892-013-0378-8 doi (NATIONALLICENCE)springer-10.1007/s11892-013-0378-8 The Future of Thiazolidinedione Therapy in the Management of Type 2 Diabetes Mellitus [Elektronische Daten] [Hanford Yau, Kathya Rivera, Romina Lomonaco, Kenneth Cusi] Since their approval, thiazolidinediones (TZDs) have been used extensively as insulin-sensitizers for the management of type 2 diabetes mellitus (T2DM). Activation of peroxisomal proliferator-activated receptor gamma (PPARγ) nuclear receptors by TZDs leads to a vast spectrum of metabolic and antiinflammatory effects. In the past decade, clinicians and scientists across the fields of metabolism, diabetes, liver disease (NAFLD), atherosclerosis, inflammation, infertility, and even cancer have had high hopes about the potential for TZDs to treat many of these diseases. However, an increasing awareness about undesirable "off-target” effects of TZDs have made us rethink their role and be more cautious about the long-term benefits and risks related to their use. This review examines the most relevant work on the benefits and risks associated with TZD treatment, with a focus on the only PPARγ agonist currently available (pioglitazone), aiming to offer the reader a balanced overview about the current and future role of TZDs in the management of insulin-resistant states and T2DM. Springer Science+Business Media New York, 2013 Thiazolidinedione nationallicence Peroxisomal proliferator-activated receptor-γ nationallicence Pioglitazone nationallicence Rosiglitazone nationallicence Type 2 diabetes mellitus nationallicence Insulin resistance nationallicence Dyslipidemia nationallicence Nonalcoholic fatty liver disease nationallicence Nonalcoholic steatoh epatitis nationallicence Polycystic ovarian syndrome nationallicence Yau Hanford Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, The University of Florida North Florida/South Georgia Veterans Health System, Gainesville, Florida, USA aut Rivera Kathya Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, The University of Florida North Florida/South Georgia Veterans Health System, Gainesville, Florida, USA aut Lomonaco Romina Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, The University of Florida North Florida/South Georgia Veterans Health System, Gainesville, Florida, USA aut Cusi Kenneth Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, The University of Florida North Florida/South Georgia Veterans Health System, Gainesville, Florida, USA aut Current Diabetes Reports Current Science Inc. 13/3(2013-06-01), 329-341 1534-4827 13:3<329 2013 13 11892 https://doi.org/10.1007/s11892-013-0378-8 text/html Onlinezugriff via DOI 1 review-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s11892-013-0378-8 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Yau Hanford Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, The University of Florida North Florida/South Georgia Veterans Health System, Gainesville, Florida, USA aut NATIONALLICENCE 700 1- Rivera Kathya Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, The University of Florida North Florida/South Georgia Veterans Health System, Gainesville, Florida, USA aut NATIONALLICENCE 700 1- Lomonaco Romina Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, The University of Florida North Florida/South Georgia Veterans Health System, Gainesville, Florida, USA aut NATIONALLICENCE 700 1- Cusi Kenneth Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, The University of Florida North Florida/South Georgia Veterans Health System, Gainesville, Florida, USA aut NATIONALLICENCE 773 0- Current Diabetes Reports Current Science Inc 13/3(2013-06-01), 329-341 1534-4827 13:3<329 2013 13 11892 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer